7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and on Androgen Replacement Therapy

Description

This study evaluates 7 Tesla (T) magnetic resonance imaging (MRI) in observing changes in the brain (neuroimaging) in testicular cancer patients who have decreased testosterone (hypogonadism) and are on testosterone (androgen) replacement therapy. Symptoms of hypogonadism can include fatigue, weakness, loss of libido, depression, poor concentration and erectile dysfunction. Some patients experience mental changes after diagnosis and treatment. There is some evidence that hypogonadism produces structural changes in the brain. The 7T MRI uses radio waves and a very powerful magnet linked to a computer to create detailed pictures of areas inside the body. This study may help researchers learn if 7T MRI can produce better images to assess the changes in the brain structure of testicular patients with hypogonadism and on androgen replacement therapy (ART).

Conditions

Hypogonadism, Malignant Testicular Germ Cell Tumor

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates 7 Tesla (T) magnetic resonance imaging (MRI) in observing changes in the brain (neuroimaging) in testicular cancer patients who have decreased testosterone (hypogonadism) and are on testosterone (androgen) replacement therapy. Symptoms of hypogonadism can include fatigue, weakness, loss of libido, depression, poor concentration and erectile dysfunction. Some patients experience mental changes after diagnosis and treatment. There is some evidence that hypogonadism produces structural changes in the brain. The 7T MRI uses radio waves and a very powerful magnet linked to a computer to create detailed pictures of areas inside the body. This study may help researchers learn if 7T MRI can produce better images to assess the changes in the brain structure of testicular patients with hypogonadism and on androgen replacement therapy (ART).

A Pilot Study of 7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and Androgen Replacement Therapy

7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and on Androgen Replacement Therapy

Condition
Hypogonadism
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Los Angeles County-USC Medical Center, Los Angeles, California, United States, 90033

Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Males age \>= 18 years
  • * Diagnosed with germ cell tumor of the testis (seminoma or non-seminoma) and treated with radical orchiectomy
  • * Diagnosed with hypogonadism and started androgen replacement therapy 6 months prior (+/- 2 weeks)
  • * Ability to understand and the willingness to sign a written informed consent
  • * Ability to undergo imaging procedure without any form of sedation
  • * History of any neuropsychiatric disease
  • * History of narcotic use or psychiatric medications
  • * History of ART prior to current ART regimen
  • * Standard contraindications for MRI:
  • * Prior work as a machinist or metal worker, or history of metal being removed from the eyes
  • * Cardiac pacemaker or internal pacing wires
  • * Non-MRI compatible vena cava filter, vascular aneurysm clip, heart valve, spinal or ventricular shunt, optic implant, neuro-stimulator unit, ocular implant, or intrauterine device, or
  • * Claustrophobia, or uncontrollable motion disorder
  • * Current active second malignancy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Southern California,

Mark S Shiroishi, MD, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

2026-10-29